このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Verastem 将来の成長

Future 基準チェック /26

Verastemは、37.3%と63%でそれぞれ年率37.3%で利益と収益が成長すると予測される一方、EPSはgrowで42.8%年率。

主要情報

37.3%

収益成長率

42.8%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	63.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	03 Jun 2024

今後の成長に関する最新情報

Recent updates

Verastem to highlight potential of ovarian cancer therapy on upcoming investor event

May 26

Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week

May 25

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Mar 02

What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?

Feb 02

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines

Jan 12

業績と収益の成長予測

NasdaqCM:VSTM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	65	-95	-112	-129	6
12/31/2025	16	-119	-108	-110	8
12/31/2024	0	-119	-117	-116	8
3/31/2024	N/A	-106	-95	-94	N/A
12/31/2023	N/A	-87	-86	-86	N/A
9/30/2023	N/A	-77	-73	-73	N/A
6/30/2023	N/A	-75	-72	-72	N/A
3/31/2023	N/A	-73	-65	-65	N/A
12/31/2022	3	-74	-64	-64	N/A
9/30/2022	3	-73	-57	-57	N/A
6/30/2022	3	-78	-53	-53	N/A
3/31/2022	4	-73	-53	-53	N/A
12/31/2021	2	-71	-54	-54	N/A
9/30/2021	2	-75	-65	-65	N/A
6/30/2021	81	-39	-10	-10	N/A
3/31/2021	84	-45	-19	-19	N/A
12/31/2020	89	-68	-34	-34	N/A
9/30/2020	92	-87	-49	-49	N/A
6/30/2020	22	-130	-122	-122	N/A
3/31/2020	21	-149	-134	-134	N/A
12/31/2019	17	-149	-139	-139	N/A
9/30/2019	15	-122	-143	-120	N/A
6/30/2019	22	-113	-138	-115	N/A
3/31/2019	28	-89	-114	-91	N/A
12/31/2018	27	-72	-98	-75	N/A
9/30/2018	26	-79	-77	-76	N/A
6/30/2018	10	-81	-66	-65	N/A
3/31/2018	N/A	-76	-69	-69	N/A
12/31/2017	N/A	-68	N/A	-57	N/A
9/30/2017	N/A	-61	N/A	-43	N/A
6/30/2017	N/A	-46	N/A	-37	N/A
3/31/2017	N/A	-41	N/A	-29	N/A
12/31/2016	N/A	-36	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-44	N/A	-39	N/A
3/31/2016	N/A	-51	N/A	-45	N/A
12/31/2015	N/A	-58	N/A	-46	N/A
9/30/2015	N/A	-60	N/A	-45	N/A
6/30/2015	N/A	-58	N/A	-43	N/A
3/31/2015	N/A	-55	N/A	-39	N/A
12/31/2014	N/A	-53	N/A	-37	N/A
9/30/2014	N/A	-51	N/A	-34	N/A
6/30/2014	N/A	-48	N/A	-32	N/A
3/31/2014	N/A	-45	N/A	-29	N/A
12/31/2013	N/A	-41	N/A	-26	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VSTM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VSTM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VSTM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VSTMの収益 ( 63% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: VSTMの収益 ( 63% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VSTMの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Verastem 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Price target decreased by 8.5% to US$4.30

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Recent updates

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

Does Verastem (NASDAQ:VSTM) Have A Healthy Balance Sheet?

Verastem to highlight potential of ovarian cancer therapy on upcoming investor event

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Consensus revenue estimates increase to US$1.23m

Analysts Are Betting On Verastem, Inc. (NASDAQ:VSTM) With A Big Upgrade This Week

Consensus revenue estimates fall to US$1.01m

First quarter 2021 earnings released: US$0.088 loss per share (vs US$0.35 loss in 1Q 2020)

Verastem, Inc. Reports Updated Data from the LGSOC Cohort of the Ongoing, Investigator-Sponsored Phase 1/2 Frame Study Evaluating Vs-6766 in Combination with Defactinib in Patients with Recurrent LGSOC

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.00 loss in FY 2019)

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

What Is The Ownership Structure Like For Verastem, Inc. (NASDAQ:VSTM)?

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines